These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 2511024)
1. Relationship between the metabolism of antipyrine, hexobarbital and theophylline in patients with liver disease as assessed by a 'cocktail' approach. Schellens JH; Janssens AR; van der Wart JH; van der Velde EA; Breimer DD Eur J Clin Invest; 1989 Oct; 19(5):472-9. PubMed ID: 2511024 [TBL] [Abstract][Full Text] [Related]
2. Relationship between the metabolism of antipyrine, hexobarbitone and theophylline in man as assessed by a 'cocktail' approach. Schellens JH; van der Wart JH; Danhof M; van der Velde EA; Breimer DD Br J Clin Pharmacol; 1988 Oct; 26(4):373-84. PubMed ID: 3190987 [TBL] [Abstract][Full Text] [Related]
3. Correlation between the in vivo metabolism of hexobarbital and antipyrine in rats with a portacaval shunt. van der Graaff M; Vermeulen NP; Joeres RP; Breimer DD Pharmacology; 1984; 29(2):99-109. PubMed ID: 6473507 [TBL] [Abstract][Full Text] [Related]
4. The influence of dietary restriction on the metabolism of theophylline and antipyrine in the ageing female BN/BiRij rat. Groen K; Breimer DD; Brouwer A; Schijff G; Jansen EJ; van Bezooijen CF J Pharmacol Exp Ther; 1995 Jul; 274(1):143-7. PubMed ID: 7616391 [TBL] [Abstract][Full Text] [Related]
5. The influence of aging on the metabolism of simultaneously administered hexobarbital enantiomers and antipyrine before and after phenobarbital induction in male rats: a longitudinal study. Groen K; Breimer DD; Jansen EJ; van Bezooijen CF J Pharmacol Exp Ther; 1994 Feb; 268(2):531-6. PubMed ID: 8113964 [TBL] [Abstract][Full Text] [Related]
6. Correlation between the in vivo metabolism of hexobarbital and antipyrine in rats. van der Graaff M; Vermeulen NP; Joeres RP; Vlietstra T; Breimer DD J Pharmacol Exp Ther; 1983 Nov; 227(2):459-65. PubMed ID: 6631725 [TBL] [Abstract][Full Text] [Related]
7. Metabolism of simultaneously administered antipyrine and theophylline in male BN/BiRij rats before and after induction with 3-methylcholanthrene. Groen K; Breimer DD; van Bezooijen CF Drug Metab Dispos; 1992; 20(4):502-6. PubMed ID: 1356725 [TBL] [Abstract][Full Text] [Related]
8. Antipyrine, theophylline, and hexobarbital as in vivo P450 probe drugs. Groen K; Breimer DD Methods Enzymol; 1996; 272():169-77. PubMed ID: 8791775 [No Abstract] [Full Text] [Related]
9. Effects of interferon-alpha monotherapy on hepatic drug metabolism in cancer patients. Israel BC; Blouin RA; McIntyre W; Shedlofsky SI Br J Clin Pharmacol; 1993 Sep; 36(3):229-35. PubMed ID: 9114909 [TBL] [Abstract][Full Text] [Related]
10. Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis. Teunissen MW; Spoelstra P; Koch CW; Weeda B; van Duyn W; Janssens AR; Breimer DD Br J Clin Pharmacol; 1984 Nov; 18(5):707-15. PubMed ID: 6508980 [TBL] [Abstract][Full Text] [Related]
11. Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans. Abernethy DR; Egan JM; Dickinson TH; Carrum G J Pharmacol Exp Ther; 1988 Mar; 244(3):994-9. PubMed ID: 3252045 [TBL] [Abstract][Full Text] [Related]
12. Induction of hexobarbital and antipyrine metabolism by rifampicin treatment in the pig. van den Broek JM; Teunissen MW; Breimer DD Drug Metab Dispos; 1981; 9(6):541-4. PubMed ID: 6120813 [TBL] [Abstract][Full Text] [Related]
13. Correlation between antipyrine metabolite formation and theophylline metabolism in humans after simultaneous single-dose administration and at steady state. Teunissen MW; De Leede LG; Boeijinga JK; Breimer DD J Pharmacol Exp Ther; 1985 Jun; 233(3):770-5. PubMed ID: 4009489 [TBL] [Abstract][Full Text] [Related]
14. Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Engel G; Hofmann U; Heidemann H; Cosme J; Eichelbaum M Clin Pharmacol Ther; 1996 Jun; 59(6):613-23. PubMed ID: 8681486 [TBL] [Abstract][Full Text] [Related]
15. Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism. Shedlofsky SI; Israel BC; McClain CJ; Hill DB; Blouin RA J Clin Invest; 1994 Dec; 94(6):2209-14. PubMed ID: 7989576 [TBL] [Abstract][Full Text] [Related]
16. Influence of liver damage on antipyrine metabolite formation in rats. Tanaka E; Etoh H; Ishikawa A; Nakano M; Misawa S Xenobiotica; 1991 May; 21(5):663-7. PubMed ID: 1949899 [TBL] [Abstract][Full Text] [Related]
18. Relationship between antipyrine metabolism and acetylation phenotype in health and chronic liver diseases. el-Yazigi A; Raines DA; Wahab FA; Sieck JO; Ernst P; Ali H; Dossing M J Clin Pharmacol; 1995 Jun; 35(6):615-21. PubMed ID: 7665722 [TBL] [Abstract][Full Text] [Related]
19. Changes in metabolism and urinary excretion of antipyrine induced by aerobic conditioning. Villa JG; Bayon JE; González-Gallego J J Sports Med Phys Fitness; 1999 Sep; 39(3):197-201. PubMed ID: 10573660 [TBL] [Abstract][Full Text] [Related]
20. Antipyrine clearance and metabolite formation: the influence of liver volume and smoking. Spoelstra P; Teunissen MW; Janssens AR; Weeda B; van Duijn W; Koch CW; Breimer DD Eur J Clin Invest; 1986 Aug; 16(4):321-7. PubMed ID: 3093244 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]